|
Tuesday June 10
|
| 18.30-20.00 |
Registration at the Cruise Terminal |
| |
|
|
|
| 20.30-22.30 |
Welcome reception at the Santísima Trinidad located in front of Hotel Melia |
| |
|
|
|
|
Wednesday June 11
|
| 08:00-08:45 |
Registration |
| |
|
|
|
| 08:45-09:00 |
Welcome and Introduction |
| |
|
|
|
| 09:00-10:20 |
OrBiTo and Mechanistic absorption modelling |
Chair: Leon Aarons and Panos Macheras
|
| 09:00-09:40 |
Amin Rostami-Hodjegan |
OrBiTo - translating mechanistic knowledge on absorption into predictive models |
| 09:40-10:00 |
Benjamin Guiastrennec |
Mechanism-based modelling of gastric emptying and bile release in response to caloric intake |
| 10:00-10:20 |
Andrés Olivares-Morales |
An in silico physiologically-based pharmacokinetic (PBPK) study of the impact of the drug release rate on oral absorption, gut wall metabolism and relative bioavailability |
| |
|
|
|
| 10:20-11:50 |
Coffee break, Poster and Software session I |
| |
Posters in Group I (with poster numbers starting with I-) are accompanied by their presenter |
| |
|
|
|
| 11:50-12:40 |
Facilitating Modelling and Simulation |
Chair: Charlotte Kloft
|
| 11:50-12:10 |
Kapil Gadkar |
Development of Virtual Population for a Quantitative Systems Pharmacology model |
| 12:10-12:30 |
Maciej Swat |
PharmML 1.0 – An Exchange Standard for Models in Pharmacometrics |
| 12:30-12:40 |
Marc Gastonguay |
Proposal for a Web-Based Open Pharmacometrics Curriculum |
| |
|
|
|
| 12:40-14:10 |
Lunch |
| |
|
|
|
| 14:10-15:10 |
Model-based individualisation |
Chair: Nick Holford
|
| 14:10-14:50 |
Pierre Marquet |
Implementing model-based individualization in the clinic |
| 14:50-15:10 |
Núria Buil Bruna |
A step forward toward personalised medicine in oncology: Population modelling for the early prediction of disease progression using biomarkers |
| |
|
|
|
| 15:10-16:30 |
Tea break, Poster and Software session II |
| |
Posters in Group II (with poster numbers starting with II-) are accompanied by their presenter |
| |
|
|
|
| 16:30-17:50 |
Drug/Disease modeling |
Chair: Oscar Della Pasqua
|
| 16:30-16:50 |
Julia Korell |
Application of a model based longitudinal network meta-analysis of FEV1 in COPD trials in clinical drug development |
| 16:50-17:10 |
Sebastian Weber |
Bayesian Drug Disease Model with Stan - Using published longitudinal data summaries in population models
|
| 17:10-17:30 |
Angelica Quartino |
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer's Disease |
| 17:30-17:50 |
Yaming Hang |
Pharmacokinetic and Pharmacodynamic Analysis Longitudinal Gd-Enhanced Lesion Count in Subjects with Relapsing Remitting Multiple Sclerosis Treated with Peginterferon beta-1a |
| |
|
|
|
|
Thursday June 12
|
| 08:45-10:05 |
Lewis Sheiner Student Session |
Chair: Emmanuelle Comets, Joachim Grevel and Panos Macheras
|
| 08:45-09:10 |
Thi Huyen Tram Nguyen |
Handling data below the quantification limit in viral kinetic modeling for model evaluation and prediction of treatment outcome |
| 09:10-09:35 |
Nikolaos Tsamandouras |
Development of population based approaches to describe the complex pharmacokinetics of simvastatin in different individuals. Bridging the gap between population and physiologically based pharmacokinetic modelling |
| 09:35-10:00 |
Mélanie Wilbaux |
A dynamic K-PD joint model for the kinetics of CTC (Circulating Tumor Cell) count and PSA concentration during treatment in metastatic castration-resistant prostate cancer |
| 10.00-10.05 |
Presentation of Lewis Sheiner student session awards |
| |
|
|
|
| 10:05-11:30 |
Coffee break, Poster and Software session I |
| |
Posters in Group III (with poster numbers starting with III-) are accompanied by their presenter |
| |
|
|
|
| 11:30-12:50 |
Regulators and EFPIA initiatives for Modeling Informed Drug Discovery and Development (MID3) |
Chair: Dinesh Dealwis and Marylore Chenel
|
| 11:30-11:50 |
Scott Marshall |
Proposed Modelling and Simulation good practices: Progress post EMA / EFPIA M&S workshop |
| 11:50-12:15 |
Terry Shepard |
How European Regulators are Facilitating the Use of Modelling and Simulation: MSWG History, Activity and Future |
| 12:15-12:35 |
Efthymios Manolis |
EMA qualification of novel methodologies: are we ready for M&S? |
| 12.35-12.50 |
Panel discussion |
| |
|
|
|
| 12:50-14:15 |
Lunch |
| |
|
|
|
| 14:15-15:15 |
Regulators and EFPIA initiatives for Modeling Informed Drug Discovery and Development (MID3) continued |
Chair: Mick Looby and Dinesh Dealwis
|
| 14:15-14:40 |
Bjoern Bornkamp |
The MCP-Mod methodology – A statistical methodology for dose-response modelling |
| 14:40-15:15 |
Vikram Sinha |
The role of MBDD in drug development - is it time to repaint the canvas? |
| |
|
|
|
| 15:15-16:40 |
Tea break, Poster and Software session IV |
| |
Posters in Group IV (with poster numbers starting with IV-) are accompanied by their presenter |
| |
|
|
|
| 16:40-17:20 |
Pharmacometric models for dose-finding and cost effectiveness |
Chair: Lena Friberg
|
| 16:40-17:00 |
Camille Vong |
In silico comparison of MTD determination in a phase I dose-finding framework |
| 17:00-17:20 |
Coen van Hasselt |
Towards early integrated mechanism-based prediction of clinical outcome and cost-effectiveness in castration-resistant prostate cancer |
| |
|
|
|
|
Friday June 13
|
| 09:00-10:00 |
Stuart Beal Methodology Session |
Chair: France Mentré
|
| 09:00-09:20 |
Edouard Ollier |
Group comparison with fused lasso penalized likelihood: an alternative to test based methods |
| 09:20-09:40 |
Elin Svensson |
Prediction of pharmacokinetic interactions for drugs with a long half-life – evidence for the need of model-based analysis |
| 09:40-10:00 |
Yasunori Aoki |
Averaged Model Based Decision Making for Dose Selection Studies |
| |
|
|
|
| 10.00-10.05 |
Preview of PAGE 2015 |
| |
|
|
|
| 10:00-10:40 |
Coffee break and Software session |
| |
|
|
|
| 10:50-12:10 |
Modelling in oncology |
Chair: René Bruno
|
| 10:50-11:10 |
Sharon Hori |
Modeling cancer blood biomarker dynamics in relation to tumor growth |
| 11:10-11:30 |
Rik de Greef |
Modeling of tumor size reduction patterns in advanced melanoma under treatment with MK-3475, a potent antibody against PD-1 |
| 11:30-11:50 |
Pauline Mazzocco |
A mixed-effect modeling framework to personalize treatment of low-grade glioma patients |
| 11:50-12:10 |
Nick Holford |
Power and Type 1 Error of Tumour Size Metrics Used to Predict Survival |
| |
|
|
|
| 12.10-12.20 |
Closing remarks |
| |
|
|
|
| 12:20-12:40 |
Audience Input for the PAGE 2015 Program |
